Insider buying
~$42K15K sh @ $2.82
First insider buy since Oct 2023Traded Nov 18 · filed 2 days later
Since the trade −20.9% · S&P 500 −2.0% · to Nov 19
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
NMAD · NASDAQ · Pharmaceutical Preparations
Nomad Power Solutions (NMAD) · oqro.io/stocks/NMAD · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$2.56+0.305 (+13.53%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Yes. Insiders of Nomad Power Solutions (NMAD) filed 3 open-market purchases in the last 90 days; the latest was filed on Nov 20, 2026.
Since 2016, Nomad Power Solutions insiders reported 37 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 7 different years, most recently 2026.
No open-market sale by an insider of Nomad Power Solutions (NMAD) was filed with the SEC in the last 90 days.
No trade in Nomad Power Solutions (NMAD) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−65.1% (−$4.78) from Jul 6, 2026 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $7.34 on Jul 6, 2026 to $2.56 on Nov 20, 2026 (−65.1%). Disclosed in this range: 3 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Boca Raton, Fl.
Last 12 months
Not enough history
Market value
$36.3M
Short interest: 960K shares sold short (6.0% of shares outstanding), +6.4% vs the previous count, 4.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Insider buying
First insider buy since Oct 2023Traded Nov 18 · filed 2 days later
Since the trade −20.9% · S&P 500 −2.0% · to Nov 19
Traded Nov 18, 2026 · largest single transaction ~$8.4K
Nov 18, 2026~$8.4K · 3,000 sh @ $2.79
DetailsOfficial recordNov 18, 2026~$5.9K · 2,000 sh @ $2.95
DetailsOfficial recordFund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Nomad Power Solutions reported 37 open-market purchases and 0 sales since 2016; purchases in 7 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $57K3×3 trades | — |
| 2023 | $52K3×3 trades | — |
| 2022 | $122K16×16 trades | — |
| 2020 | $1.5M7×7 trades | — |
| 2018 | $1.25M4×4 trades | — |
| 2017 | $60K1×1 trade | — |
| 2016 | $17K3×3 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Jul 6, 2026, NMAD is down 69.3% and the index fund is down 4.7%: 65 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much NMAD moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
North York Ltd
13G · passive · Crossed 5% · 1.84M shares · filed Oct 28, 2026
Geordan Pursglove
13G · passive · Crossed 5% · 2.12M shares · filed Nov 16, 2026
Beneth Capital LLC
13G · passive · Crossed 5% · 1.49M shares · filed Nov 16, 2026
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Top officer leaving
“Departure of Chief Executive Officer On November 9, 2026, Geordan Pursglove stepped down as Chief Executive Officer of Nomad Power Solutions, Inc.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
Latest annual report filed Mar 31, 2026. Read the filing
The risk factors section was largely rewritten: most of its 9 headings have no close match among the 65 of the year before, so no list of changes is shown.
On November 19, 2025, the Company received a written demand from FX Group Inc. and certain related parties (“FX”), asserting that FX was entitled to consulting fees in connection with capital offerings completed by the Company during June and July 2025. The Company denied the allegations, and negotiations continued after year-end. On January 22, 2026, the Company entered into a settlement agreement, under which the Company agreed to pay a one-time settlement amount of $100,000 to FX in exchange for mutual releases of all claims.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Revenue
$472K
−27.6% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt $6.61M, cash —, at Dec 31, 2025
Net income, last 12 months
—
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Off-exchange trading: 41.4% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (13.4% on ATS, 28.0% with other brokers), below its 15-week average of 49.2%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (19.2%), SIGMA X2 (14.1%), INTELLIGENT CROSS LLC (14.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 13,000 words.
Overview The Company is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company is the majority shareholder of Liora Technologies Europe Ltd., which is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. The Company’s corporate office is located in Boca Raton, Florida. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.